{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:57:52Z","timestamp":1780567072579,"version":"3.54.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Many types of cancer such as prostate cancer, myeloid leukemia, breast cancer, glioblastoma display strong chemo resistance, which is supported by enhanced expression of multiple anti-apoptotic Bcl-2, Bcl-XL and Mcl-1 proteins. The viable anti-cancer strategies are based on developing anti-apoptotic Bcl-2 proteins inhibitors, BH3 mimetics. Our focus in past years has been on the investigating a new potential BH3 mimetic, Hypericin (Hyp). Hyp is a naturally occurring photosensitive compound used in photodynamic therapy and diagnosis. We have demonstrated that Hyp can cause substantial effects in cellular ultrastructure, mitochondria function and metabolism, and distribution of Bcl2 proteins in malignant and non-malignant cells. One of the possible mechanisms of Hyp action could be the direct interactions between Bcl-2 proteins and Hyp. We investigated this assumption by in silico computer modelling and <jats:italic>in vitro<\/jats:italic> fluorescent spectroscopy experiments with the small Bcl2 peptide segments designed to correspond to Bcl2 BH3 and BH1 domains. We show here that Hyp interacts with BH3 and BH1 peptides in concentration dependent manner, and shows the stronger interactions than known BH3 mimetics, Gossypol (Goss) and ABT-263. In addition, interactions of Hyp, Goss and ABT263, with whole purified proteins Bcl-2 and Mcl-1 by fluorescence spectroscopy show that Hyp interacts stronger with the Bcl-2 and less with Mcl-1 protein than Goss or ABT-263. This suggest that Hyp is comparable to other BH3 mimetics and could be explore as such. Hyp cytotoxicity was low in human U87 MG glioma, similar to that of ABT263, where Goss exerted sufficient cytotoxicity, suggesting that Hyp acts primarily on Bcl-2, but not on Mcl-1 protein. In combination therapy, low doses of Hyp with Goss effectively decreased U87 MG viability, suggesting a possible synergy effect. Overall, we can conclude that Hyp as BH3 mimetic acts primarily on Bcl-2 protein and can be explored to target cells with Bcl-2 over-expression, or in combination with other BH3 mimetics, that target Mcl-1 or Bcl-XL proteins, in dual therapy.<\/jats:p>","DOI":"10.3389\/fphar.2022.991554","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T06:41:47Z","timestamp":1664865707000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Hypericin, a potential new BH3 mimetic"],"prefix":"10.3389","volume":"13","author":[{"given":"Anastasia","family":"Doroshenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tomkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Kozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Stroffekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1006\/bbrc.1996.0451","article-title":"A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives","volume":"220","author":"Agostinis","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/0006-2952(95)00097-j","article-title":"Photosensitized inhibition of growth factor-regulated protein kinases by hypericin","volume":"49","author":"Agostinis","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s1357-2725(01)00126-1","article-title":"Hypericin in cancer treatment: More light on the way","volume":"34","author":"Agostinis","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/sj.onc.1204288","article-title":"Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event","volume":"20","author":"Annis","year":"2001","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcp.21567","article-title":"Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy","volume":"218","author":"Azmi","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4149\/gpb_2013021","article-title":"Bcl-2 proapoptotic proteins distribution in U-87 MG glioma cells before and after hypericin photodynamic action","volume":"32","author":"Balogova","year":"2013","journal-title":"Gen. Physiol. Biophys."},{"key":"B7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jphotobiol.2010.06.004","article-title":"Comparative in vitro study on the characteristics of different photosensitizers employed in PDT","volume":"100","author":"Berlanda","year":"2010","journal-title":"J. Photochem. Photobiol. B"},{"key":"B8","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/ijc.20285","article-title":"Antimetastatic activity of the photodynamic agent hypericin in the dark","volume":"111","author":"Blank","year":"2004","journal-title":"Int. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"key":"B10","first-page":"737","article-title":"In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo","volume":"6","author":"Chmura","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.bbamcr.2015.03.012","article-title":"Emerging understanding of bcl-2 biology: Implications for neoplastic progression and treatment","volume":"1853","author":"Correia","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8590","DOI":"10.1038\/sj.onc.1207102","article-title":"The bcl-2 family: Roles in cell survival and oncogenesis","volume":"22","author":"Cory","year":"2003","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0092-8674(04)00046-7","article-title":"Cell death: Critical control points.","volume":"116","author":"Danial","year":"2004","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"102343","DOI":"10.1016\/j.pdpdt.2021.102343","article-title":"Hypericin in photobiological assays: An overview","volume":"35","author":"de Andrade","year":"2021","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1038\/emboj.2010.177","article-title":"An intimate liaison: Spatial organization of the endoplasmic reticulum-mitochondria relationship","volume":"29","author":"de Brito","year":"2010","journal-title":"EMBO J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jmb.2012.05.022","article-title":"Predictive Bcl-2 family binding models rooted in experiment or structure","volume":"422","author":"DeBartolo","year":"2012","journal-title":"J. Mol. Biol."},{"key":"B18","volume-title":"Medicinal natural products: A biosynthetic approach","author":"Dewick","year":"2002"},{"key":"B19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pdpdt.2014.02.010","article-title":"The role of anti-apoptotic protein kinase C\u03b1 in response to hypericin photodynamic therapy in U-87 MG cells","volume":"11","author":"Dzurova","year":"2014","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0234103","DOI":"10.1371\/journal.pone.0234103","article-title":"Fadraciclib (CYC065), a novel CDK inhibitor, targets key prosurvival and oncogenic pathways in cancer","volume":"15","author":"Frame","year":"2020","journal-title":"PLoS ONE"},{"key":"B21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1006\/cbir.2001.0768","article-title":"Expression of BAX in cell nucleus after experimentally induced apoptosis revealed by immunogold and embedment-free electron microscopy","volume":"25","author":"Gajkowska","year":"2001","journal-title":"Cell Biol. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: Pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1751-1097.2012.01217.x","article-title":"Photodynamic mechanisms induced by a combination of hypericin and a chlorin based-photosensitizer in head and neck squamous cell carcinoma cells","volume":"89","author":"Gyenge","year":"2013","journal-title":"Photochem. Photobiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"19484","DOI":"10.1021\/jp051645u","article-title":"Interaction of glutathione S-transferase with hypericin: A photophysical study","volume":"109","author":"Halder","year":"2005","journal-title":"J. Phys. Chem. B"},{"key":"B25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tiv.2017.01.005","article-title":"Assessing light-independent effects of hypericin on cell viability, ultrastructure and metabolism in human glioma and endothelial cells","volume":"40","author":"Huntosova","year":"2017","journal-title":"Toxicol. In. Vitro"},{"key":"B26","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ijms11020562","article-title":"Hypericins as potential leads for new therapeutics","volume":"11","author":"Karioti","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2174\/092986706777935267","article-title":"Cellular mechanisms and prospective applications of hypericin in photodynamic therapy","volume":"13","author":"Kiesslich","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy.","year":"2016","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-46312-4","volume-title":"Principles of fluorescence spectroscopy","author":"Lakowicz","year":"2006"},{"key":"B31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pdpdt.2014.01.002","article-title":"The interrelation between a pro-inflammatory milieu and fluorescence diagnosis or photodynamic therapy of human skin cell lines","volume":"11","author":"Larisch","year":"2014","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"521281","DOI":"10.1155\/2013\/521281","article-title":"In vitro analysis of photosensitizer accumulation for assessment of applicability of fluorescence diagnosis of squamous cell carcinoma of epidermolysis bullosa patients","volume":"2013","author":"Larisch","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2018.06.019","article-title":"ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells","volume":"432","author":"Lee","year":"2018","journal-title":"Cancer Lett."},{"key":"B34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/cdd.2010.74","article-title":"A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2\u2013Beclin1 interaction at endoplasmic reticulum","volume":"18","author":"Lian","year":"2011","journal-title":"Cell Death Differ."},{"key":"B35","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molcel.2011.10.001","article-title":"A unified model of mammalian BCL-2 protein family interactions at the mitochondria","volume":"44","author":"Llambi","year":"2011","journal-title":"Mol. Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4161\/auto.4237","article-title":"BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2\/Bcl-XL","volume":"3","author":"Maiuri","year":"2007","journal-title":"Autophagy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1562\/0031-8655(2001)074<0120:acaohi>2.0.co;2","article-title":"ANTI-cancer activities of hypericin in the dark","volume":"74","author":"Mandel","year":"2007","journal-title":"Photochem. Photobiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejphar.2005.03.047","article-title":"Hypericin in the dark inhibits key steps of angiogenesis in vitro","volume":"516","author":"Martinez-Poveda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1389450023348091","article-title":"Hypericin\u2014a new antiviral and antitumor photosensitizer: Mechanism of action and interaction with biological macromolecules","volume":"3","author":"Miskovsky","year":"2002","journal-title":"Curr. Drug Targets"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1021\/jp711513b","article-title":"Solvent effects on the fluorescence quenching of tryptophan by amides via electron transfer. Experimental and computational studies","volume":"113","author":"Muino","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3892\/ijo.2011.968","article-title":"Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results","volume":"38","author":"Noell","year":"2011","journal-title":"Int. J. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bbcan.2004.09.004","article-title":"Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy","volume":"1705","author":"O\u2019Neill","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.bcp.2017.03.006","article-title":"Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects","volume":"136","author":"Opydo-Chanek","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbamcr.2003.08.012","article-title":"Structural biology of the Bcl-2 family of proteins","volume":"1644","author":"Petros","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"B46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ijbiomac.2011.11.021","article-title":"Peptide screening to knockdown bcl-2\u2019s anti-apoptotic activity: Implications in cancer treatment","volume":"50","author":"Raghav","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bioorg.2007.03.001","article-title":"Structure based discovery of a new class of Bcl-xL antagonists","volume":"35","author":"Rega","year":"2007","journal-title":"Bioorg. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.280.5370.1763","article-title":"Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses","volume":"280","author":"Rizzuto","year":"1998","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3892\/ijo.2014.2652","article-title":"Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2\/Mcl-1 pathway","volume":"45","author":"Sadahira","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1016\/S0006-3495(97)78323-1","article-title":"Calculation of diffusion-limited kinetics for the reactions in collision coupling and receptor cross-linking","volume":"73","author":"Shea","year":"1997","journal-title":"Biophys. J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pdpdt.2019.08.016","article-title":"Importance of Hypericin-Bcl2 interactions for biological effects at subcellular levels","volume":"28","author":"Stroffekova","year":"2019","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"9484","DOI":"10.1021\/ja961783k","article-title":"Hypericin-induced cell photosensitization involves an intracellular pH decrease","volume":"118","author":"Sureau","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1021\/mp900166q","article-title":"The multifaceted photocytotoxic profile of hypericin","volume":"6","author":"Theodossiou","year":"2009","journal-title":"Mol. Pharm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","article-title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/35055095","article-title":"Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3","volume":"3","author":"Tzung","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jphotobiol.2003.08.008","article-title":"Photodynamic effect of hypericin and a water-soluble derivative on isolated crayfish neuron and surrounding glial cells","volume":"72","author":"Uzdensky","year":"2003","journal-title":"J. Photochem. Photobiol. B"},{"key":"B59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s0092-8674(00)80564-4","article-title":"Cell death in development","volume":"96","author":"Vaux","year":"1999","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.coph.2015.05.014","article-title":"Bcl-2 family of proteins as drug targets for cancer chemotherapy: The long way of BH3 mimetics from bench to bedside","volume":"23","author":"Vela","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"943648","DOI":"10.1155\/2014\/943648","article-title":"Targeting BCL2-Proteins for the treatment of solid tumours","volume":"2014","author":"Vogler","year":"2014","journal-title":"Adv. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1541-7786.MCR-09-0562","article-title":"The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma","volume":"8","author":"Voss","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-4598-13-98","article-title":"The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1021\/jm060460o","article-title":"Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins","volume":"49","author":"Wang","year":"2006","journal-title":"J. Med. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.97.13.7124","article-title":"Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells","volume":"97","author":"Wang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B66","first-page":"1498","article-title":"Cell permeable bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells","volume":"60","author":"Wang","year":"2000","journal-title":"Cancer Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fonc.2011.00028","article-title":"An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic Bcl-2 family proteins","volume":"1","author":"Wei","year":"2011","journal-title":"Front. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.molstruc.2008.10.053","article-title":"Fluorescence spectroscopy study on the interaction between Gossypol and bovine serum albumin","volume":"920","author":"Yang","year":"2009","journal-title":"J. Mol. Struct."},{"key":"B69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4161\/auto.22805","article-title":"Autophagy-dependent EIF2AK3 activation compromises ursolic acid-induced apoptosis through upregulation of MCL1 in MCF-7 human breast cancer cells","volume":"9","author":"Zhao","year":"2013","journal-title":"Autophagy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.991554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T06:41:54Z","timestamp":1664865714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.991554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":69,"alternative-id":["10.3389\/fphar.2022.991554"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.991554","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"article-number":"991554"}}